BioPharmSignal logoBioPharmSignal

Biotech News

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Accelerate Diagnostics (AXDX)Accelerate DiagnosticsFDA / regulatory

AXDX (AXDX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is axdx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

INBSIntelligent Bio Solutions2026-06-02 12:30 EST

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

INBSIntelligent Bio Solutions2026-01-28 13:30 EST

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

OSUROraSure Technologies, Inc.2026-01-05 13:00 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

BJDXBluejay Diagnostics2025-11-10 12:30 EST

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

VRAXVirax Biolabs2025-11-03 13:29 EST

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

VRAXVirax Biolabs2025-08-26 11:30 EST

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

MDXHMDxHealth2025-08-05 20:01 EST

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

DGXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

View all latest news

Accelerate Diagnostics

Accelerate Diagnostics was a diagnostics company focused on rapid infectious-disease testing before its restructuring and decline. Its platform aimed to speed up bacterial identification and susceptibility testing.

Recent company news

AXDXAccelerate Diagnostics2025-05-08 13:00 EST

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

AXDXAccelerate Diagnostics2025-03-21 17:52 EST

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

AXDXAccelerate Diagnostics2025-03-21 12:30 EST

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

AXDXAccelerate Diagnostics2025-01-10 21:05 EST

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

AXDXAccelerate Diagnostics2024-11-07 21:05 EST

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States